FLU-VACS Comparative Study in Adults

Inclusion Criteria: Persons must be adult men and women aged 18-49 years. Persons must be able and willing to provide informed consent. Persons must expect to reside in the study area during the entire study period and be interested in participating each year. Persons must be willing to receive the licensed live-attenuated vaccine (FluMist) or placebo given as a nasal spray, or the licensed inactivated influenza vaccine (Fluzone or Fluvirin) or placebo given as an intramuscular injection. Persons must be willing to provide multiple blood specimens collected by venipuncture each year they are in the study. During each of the first two years of study, blood specimens will be collected three times - at the enrollment visit (immediately prior to administration of vaccine or placebo), at the first follow-up visit 3-5 weeks later, and at the end of the influenza season visit (approximately 4-6 months later); during the third year of the study, blood specimens will be collected twice only, at visits before and after the influenza season. Persons must be willing to notify study personnel in the event of influenza-like illness, to provide information on illness symptoms, and to permit collection of a throat culture (swab) specimen for laboratory studies. Persons must be willing to not receive an influenza vaccine while participating - other than that (influenza vaccine or placebo) received as study medication. Exclusion Criteria: Persons with any health condition for which the inactivated vaccine is recommended (Advisory Committee on Immunization Practices - ACIP) including: chronic diseases of the pulmonary or cardiovascular systems (including asthma); chronic metabolic diseases (including diabetes); renal dysfunction; hemoglobinopathies; immune deficiency disease (including HIV infection) or on-going immunosuppressive therapy. Persons who are currently pregnant, nursing mothers or planning a pregnancy within one month of vaccination. Persons with hypersensitivity to egg, egg protein, thimerosal (a preservative) or the antibiotic Gentamicin (also know as Garamycin). Persons who have had a prior serious reaction to influenza vaccine, or ever had Guillain-Barre syndrome. Persons who are living in a household with or have direction occupational contact with immunosuppressed individuals (including health care workers with direct patient contact). Persons who have received an influenza vaccine for the influenza season in which they are to be first enrolled or those who plan to receive an influenza vaccine during their participation in the study - other than that (influenza vaccine or placebo) received as study medication. Persons who have received any other vaccine within one week prior to enrollment (may delay enrollment). Persons who have had a respiratory illness or illness with fever within 3 days of study enrollment (may delay enrollment). Persons who are participating in another research study involving any study medications (medicines or vaccines).